A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.

Trial Details

NCT ID
NCT07213609
Phase
PHASE1 / PHASE2
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • GSK5460025
Locations (sample)
  • Canton, Ohio, United States|40.79895,-81.37845
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Hamilton, Ontario, Canada|43.25011,-79.84963
  • Toronto, Ontario, Canada|43.70643,-79.39864
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Has a histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor
  • Has a known dMMR/MSI-H status as determined by a certified local laboratory at the time of Pre-screening or has an unknown Mismatch repair (MMR)/ M…
  • Provides an archival or fresh (preferred) formalin fixed, paraffin embedded (FFPE) sample
  • Intends to receive GSK5460025 as next treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →